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Abstract
Background: Soluble guanylate cyclases generate cyclic GMP when bound to nitric oxide, thereby
linking nitric oxide levels to the control of processes such as vascular homeostasis and
neurotransmission. The guanylate cyclase catalytic module, for which no structure has been
determined at present, is a class III nucleotide cyclase domain that is also found in mammalian
membrane-bound guanylate and adenylate cyclases.
Results: We have determined the crystal structure of the catalytic domain of a soluble guanylate
cyclase from the green algae Chlamydomonas reinhardtii at 2.55 Å resolution, and show that it is a
dimeric molecule.
Conclusion: Comparison of the structure of the guanylate cyclase domain with the known
structures of adenylate cyclases confirms the close similarity in architecture between these two
enzymes, as expected from their sequence similarity. The comparison also suggests that the
crystallized guanylate cyclase is in an inactive conformation, and the structure provides indications
as to how activation might occur. We demonstrate that the two active sites in the dimer exhibit
positive cooperativity, with a Hill coefficient of ~1.5. Positive cooperativity has also been observed
in the homodimeric mammalian membrane-bound guanylate cyclases. The structure described here
provides a reliable model for functional analysis of mammalian guanylate cyclases, which are closely
related in sequence.
Background
The second messenger 3',5'-cyclic guanosine monophos-
phate (cGMP) is central to many signal transduction path-
ways, primarily eliciting effects by modulating the
activities of phosphodiesterases, protein kinases, and ion
channels [1-3]. In mammals, cGMP is synthesized by two
distinct classes of guanylate cyclases, which are either
cytoplasmic or membrane-bound [4]. Both classes of gua-
nylate cyclase share a catalytic module that is closely
related in sequence to that of mammalian adenylate cycla-
ses. The catalytic domain is a class III nucleotide cyclase
domain [5], which is distributed widely from bacteria to
humans. The class III nucleotide cyclase domain is often
found fused to diverse regulatory domains, but is also
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brane-bound guanylate cyclases, which respond to extra-
cellular peptide binding or to the levels of intracellular
Ca2+, function in maintenance of fluid homeostasis, inhi-
bition of myocyte hypertrophy, skeletal development,
and visual and olfactory signal transduction [9]. The
mammalian soluble guanylate cyclases are regulated pri-
marily by binding of nitric oxide (NO), and they modu-
late a wide range of physiological functions, such as
maintenance of vascular tone, platelet aggregation, and
neurotransmission [10]. Dysfunction of guanylate cyclase
signaling underlies many pathophysiological conditions,
ranging from stroke and hypertension to gastrointestinal
disease and neurodegeneration [11-13].
Mammalian soluble guanylate cyclases are heme-contain-
ing heterodimers of homologous α and β subunits [10].
The N-terminal regulatory domain of each subunit con-
tains a heme-NO and/or oxygen-binding (H-NOX)
domain [14,15], and the H-NOX domains of the β subu-
nits have been shown to bind the heme cofactor [16,17].
The homologous regions of the α subunits do not bind
heme, but are predicted to possess a similar fold. The α
and β subunits each contain a central region, shown to be
involved in heterodimerization, that consists of an H-
NOXA (H-NOX associated) domain and an amphipathic
helical extension predicted to form a coiled-coil [18,19].
The catalytic domain is located in the C-terminal segment
of the protein, and it associates with the catalytic domain
of the partner subunit to form a heterodimeric catalytic
unit [20,21]. The mechanism of soluble guanylate cyclase
activation by NO involves the binding of NO to the heme
cofactor [22], but the details of this activation mechanism
are unknown. The response of soluble guanylate cyclase
to NO is regulated allosterically by nucleotides [23,24],
but how this happens is also not understood.
The three-dimensional structure of a guanylate cyclase cat-
alytic domain has not been reported. Crystal structures
have been obtained for an oxygen-bound H-NOX domain
of a methyl-accepting chemotaxis protein from the obli-
gate anaerobe Thermoanaerobacter tencongensis [25,26] and
for NO- and carbon monoxide-bound forms of an H-
NOX domain from a histidine kinase operon in the
cyanobacterium Nostoc sp. [27], yielding clues to the
mechanism of soluble guanylate cyclase heme ligand rec-
ognition and discrimination. Additionally, the crystal
structure of the H-NOXA domain of a signal-transduction
histidine kinase from Nostoc punctiforme was reported
recently [28], revealing that the dimeric H-NOXA domain
adopts a Per/Arnt/Sim (PAS) fold and suggesting a mech-
anism for the preferential heterodimerization exhibited
by mammalian soluble guanylate cyclase. Homology
modeling based on crystal structures of the related mam-
malian and bacterial class III adenylate cyclase catalytic
domain dimers has provided some information concern-
ing the structure of the catalytic domain of the guanylate
cyclases (reviewed in [7]).
There are distinct soluble guanylate cyclases in inverte-
brates, including insects, nematodes, and algae
[25,29,30]. Also called atypical soluble guanylate cyclases,
several of these have been predicted to function as
homodimers instead of heterodimers, and a number have
been demonstrated to be regulated by oxygen [31-34].
The core subunit architecture outlined above for the
mammalian enzymes is conserved in these atypical ones,
with additional domains of unknown function appended
to the C-terminus of some of the proteins. Here, we report
the structure of the catalytic domain of a soluble guan-
ylate cyclase (CYG12) from the unicellular green algae
Chlamydomonas reinhardtii, which shares 40 to 50% iden-
tity with the soluble and membrane-bound guanylate
cyclase catalytic domains (Figure 1). The 991-residue full-
length CYG12 protein contains each of the domains
present in well-characterized soluble guanylate cyclases as
well as an additional C-terminal domain of unknown
function, and has the full complement of residues neces-
sary to function as a homodimer. As expected, the C. rein-
hardtii guanylate cyclase catalytic domain has the same
protein fold as the mammalian adenylate cyclases. With
minor differences, the positions of the residues necessary
for catalysis and nucleotide base recognition are in the
same locations for guanylate and adenylate cyclases,
although the identities of the base recognition residues
are obviously different. Compared to mammalian ade-
nylate cyclase, the crystal structure is in an inactive confor-
mation, with distorted active site structural elements.
Based on the structure, we propose a mechanism for the
positive cooperativity that is observed for mammalian
homodimeric membrane-bound guanylate cyclases and
demonstrated by us for the C. reinhardtii guanylate
cyclase. We speculate that the activation mechanism for
the guanylate cyclases involves structural rearrangement
analogous to that exhibited by the mammalian adenylate
cyclases.
Results and discussion
Structure Determination
We have determined the structure of a C. reinhardtii solu-
ble guanylate cyclase catalytic domain dimer by molecular
replacement, using the structure of the mammalian ade-
nylate cyclase heterodimer [35] as a search model. The
structure contains one catalytic domain dimer per asym-
metric unit. During refinement, we observed unexplained
peaks in electron density maps around five of the fourteen
cysteine residues in the dimer (Cys 499 and Cys 592 of
both monomers, and Cys 621 of monomer B). High con-
centrations of reductant [5–10 mM dithiothreitol and 10
mM tris(2-carboxyethyl)phosphine] were present duringPage 2 of 11
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Structural alignment of selected guanylate and adenylate cyclase catalytic domainsFigure 1
Structural alignment of selected guanylate and adenylate cyclase catalytic domains. Secondary structure annota-
tion and numbering correspond to the guanylate cyclase homolog CYG12 from C. reinhardtii. Sequences are grouped as follows: 
A, atypical soluble guanylate cyclases; B, membrane-bound guanylate cyclases; C, NO-sensing soluble guanylate cyclases; D, 
putative bacterial guanylate cyclases; E, mammalian and bacterial adenylate cyclases. Functional residues are indicated by sym-
bols: metal binding (*); ribose binding (Δ); guanine/adenine binding (r); triphosphate binding (#). Accession numbers are as fol-
lows: Chlamydomonas reinhardtii CYG12 (GenBank XP_001700847), Caenorhabditis elegans GCY35 (GenBank O02298), Rattus 
norvegicus sGCβ2 (GenBank BAB68564), Drosophila melanogaster GYC-88E (GenBank Q8INF0), Homo sapiens RetGC1 (Gen-
Bank Q02846), R. norvegicus GCA (GenBank P18910), C. elegans GCY7 (GenBank AAQ62451), Strongylocentrotus purpuratus 
mGC (GenBank P16065), R. norvegicus sGCβ1 (GenBank BAC55087), Oryzias latipes sGCβ1 (GenBank BAA76691), Manduca 
sexta sGCβ1 (GenBank AAC61264), D. melanogaster sGCβ1 (GenBank), R. norvegicus sGCα1 (GenBank AAB17953), O. latipes 
sGCα1 (GenBank BAA76690), M. sexta sGCα1 (GenBank AAC61263), D. melanogaster sGCα1 (GenBank AAF56917), Ana-
baena sp. PCC7120 all1118 (GenBank NP_485161), Nostoc punctiforme PCC73102 NpR1313 (GenBank YP_001864972), N. 
punctiforme PCC73102 NpR0352 (GenBank ACC79135), Trichodesmium erythraeum IMS101 Tery_4585 (GenBank ABG53561), 
T. erythraeum IMS101 Tery_3412 (GenBank ABG52512), Synechocystis sp. PCC6803 sll0646 (GenBank BAA16969), Canis famil-
iaris ACV_C1 (GenBank 1CJU_A), R. norvegicus ACII_C2 (GenBank 1CJU_B), Mycobacterium tuberculosis Rv1264 (GenBank 
1Y11_A), M. tuberculosis Rv1900c (GenBank 1YBU_C), Spirulina platensis CyaC (GenBank 1WC1_C). Initial alignments were 
carried out using the program ClustalX [67]. Sequences were adjusted manually with comparison to results from a structural 
homology search using the DALI server [45]. Figure 1 was prepared using the program ESPRIPT [68]. Regions containing resi-
dues of > 70% equivalence (red letters) are boxed with a thin blue line, and absolutely conserved residues are highlighted in 
red.
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or disulfide bond formation are responsible for these fea-
tures. We wondered whether the apparent modification of
the cysteine sidechains might be due to the addition of
dimethylarsenic groups via reaction of the cysteine thiol
group with the sodium cacodylate [sodium dimethylarse-
nate, (CH3)2AsO2Na] buffer and dithiothreitol reductant
present during crystallization [36]. This chemical modifi-
cation has been observed previously for several proteins
crystallized from solutions containing this buffer [37,38];
it has even been used to obtain experimental phases for
protein structure solution [39]. Accordingly, we con-
firmed the presence and location of the dimethylarsenic-
modified cysteines by taking advantage of the arsenic
anomalous signal to calculate an anomalous difference
map, which showed unambiguous peaks of electron den-
sity around the dimethylarsenic-modified cysteines (see
Additional File 1: Dimethylarsenic cysteine modifica-
tions).
The three C-terminal residues of each monomer are disor-
dered, as are residues 564–566 in monomer A and resi-
dues 562–565 in monomer B. The final model of the
guanylate cyclase dimer includes residues 467–563 and
567–653 for monomer A and residues 467–561 and 566–
653 for monomer B. The model also includes 8 phosphate
ions and 99 solvent molecules, and was refined to 2.55 Å
resolution. After refinement, the final model had working
and free R-values [40] of 17.2% and 21.5%, respectively
(Table 1).
The guanylate cyclase fold
Each guanylate cyclase domain contains a central seven-
stranded β sheet surrounded by several α helices. Second-
ary structure elements are named according to the conven-
tion for adenylate cyclases [35,41] and are indicated in
Figure 2a. The first four β strands are part of a βαββαβ
arrangement of secondary structure elements, a hallmark
of the class III nucleotide cyclase fold, several classes of
polymerase, and other nucleotidyltransferases [42-44].
Indeed, a search of the structure database with the pro-
gram DALI [45] identifies the mammalian adenylate
cyclase catalytic domains as the closest structural match,
followed by several bacterial adenylate cyclases and
polymerases. A smaller 3-stranded β sheet, formed by
strand β5 and extensions of β1 and β4 (β1a and β4b),
extends from the core of the domain, and interacts with
strands β2 and β3 of the opposite monomer to form part
of the dimer interface. The two monomers in the wreath-
like dimer [41] are related by a twofold axis, and a central
cleft, formed by the dimer interface, contains the two sym-
metric active sites (Figure 2b). The two monomers super-
impose on each other with a r.m.s. deviation of 0.3 Å for
160 structurally equivalent Cα atom pairs. The primary
structural differences between the monomers are found in
their C-terminal subdomains, particularly in the α6–β7
and β7–β8 loops, and are due to differences in crystal
packing interactions.
The structure of the guanylate cyclase catalytic domain dif-
fers from that of the adenylate cyclases primarily in the
elements that connect strands and helices, and in the less-
conserved C-terminal subdomains (Figure 1). Biochemi-
cal and structural studies have shown that these regions in
the adenylate cyclases couple to regulatory proteins such
as the heterotrimeric G-protein subunits Gsα, Giα, and
protein kinase C (reviewed in [46]). Differences in
sequence and structure between individual catalytic subu-
nits in heterodimeric adenylate and guanylate cyclases
also localize to the same regions (Figure 1).
The active site
The catalytic residues necessary for synthesizing cyclic
nucleotides, conserved across all adenylate cyclases and
guanylate cyclases (Figure 1), are contributed by structural
elements of both monomers at each active site. We will
focus on one active site, and refer to each domain as mon-
omer A or B. In the C. reinhardtii guanylate cyclase
described here, the catalytic residues are the metal-bind-
ing residues Asp 482(A) and Asp 527(A) located in the
β2–β3 loop and in strand β1b, respectively, the ribose-ori-
enting residue Asn 599(B) and the transition-state-stabi-
lizing residue Arg 603(B), both located in helixα4, and the
triphosphate-positioning residues Arg 571(A) in
strandβ4a and Lys 640(B) in the β7–β8 loop (Figure 3a).
With the exception of the critical metal-binding residue
Asp 527(A) (see below), all of these active site residues are
Table 1: Crystallographic data and refinement statistics
Data collection
Beamline ALS 8.2.2
Wavelength (Å) 1.000
Space group P3221
Unit cell a = 123.7, b = 123.7, c = 62. 8
α = 90, β = 90, γ = 120
Resolution (Å) 28-2.55 (2.7-2.55)
Rmerge (%) 7.4 (52.1)
I/σ (I) 7.6 (1.3)
Completeness (%) 96.2 (98.2)
Redundancy 4.3 (4.3)
Refinement
Unique reflections 32518
Free R test set (%) 5
Rwork/Rfree 17.2/21.5
Monomers per A. U. 2
No. atoms 2999
Protein 2860
Ligand 40
Solvent 99
r.m.s. deviation, bond lengths (Å) 0.015
r.m.s. deviation, bond angles (Å) 1.476Page 4 of 11
(page number not for citation purposes)
BMC Structural Biology 2008, 8:42 http://www.biomedcentral.com/1472-6807/8/42located at positions analogous to their location in the ade-
nylate cyclase active site (Figure 3a); minor conforma-
tional differences likely reflect the absence of metals and
nucleotides, which would assist in organizing the active
site into a catalytically competent conformation.
Modeling based on the adenylate cyclase structures has
indicated the mechanism of nucleotide base discrimina-
tion [47,48]. A glutamic acid and a cysteine, conserved in
guanylate cyclases, have been proposed to mediate recog-
nition of the exocyclic amine and carbonyl group of the
guanine base, respectively. The specificity-determining
residues in mammalian adenylate cyclase, a lysine and an
aspartic acid, are located at the same relative positions in
the adenylate cyclase protein sequence. In fact, swapping
those residues into a guanylate cyclase catalytic domain
results in conversion into an adenylate cyclase [47,48],
underscoring the equivalence of the catalytic machinery
between guanylate and adenylate cyclases. In our struc-
ture, the corresponding residues are Glu 523(B) and Cys
592(B), which are situated close to the locations of their
adenylate cyclase counterparts (Figure 3b). Local distor-
tions caused by the dimethylarsenic modifications in each
monomer appear to prevent optimal sidechain orienta-
tion for base recognition. For Cys 592(B), the dimethyl-
arsenic modification of the thiol side chain prevents
potential hydrogen bonding interaction with the exocyclic
carbonyl group of a substrate GTP molecule (Figure 3b).
The modification also results in distortion of the β2–β3
loop that contains the metal-binding residue Asp 527(A)
and the base-recognition residue Glu 523(A), causing it to
adopt a conformation incompatible with binding a metal-
nucleotide complex (Figure 3a). Together, these local dis-
tortions would likely preclude any nucleotide binding in
the active site, providing a rationale for our failure to vis-
ualize nucleotides and metals that have been soaked into
the crystals.
Guanylate cyclase activation
Activation of the mammalian adenylate cyclase has been
proposed to proceed via two steps, based on structures of
active and inactive forms of the protein [35,41,49]. In the
first step, binding of Gsα between the α1–α2 and α3–β4
loops of the C2 subunit causes a 7° rotation of the core of
the C1 subunit around an axis that runs parallel to the
central cleft, priming the active site for catalysis by bring-
ing the catalytic residues from one subunit ~2 Å closer to
the catalytic residues of the other [35]. The second step
involves the closure of the active site around the bound
nucleotide. This closure brings structural elements that
bind the metal cofactors and the nucleotide triphosphate
moiety, and residues in the opposite subunit that orient
the ribose ring and stabilize the transition state, into opti-
mal alignment for catalysis [49] (see Additional file 2:
Structural features of the guanylate cyclase domainFigure 2
Structural features of the guanylate cyclase domain. A) Structural representation of a guanylate cyclase domain mono-
mer. Elements of secondary structure are labeled according to the nomenclature depicted in Figure 1. B) The guanylate cyclase 
catalytic domain. Monomer A is colored green, and monomer B is multi-colored, ranging from blue at the N-terminus to red at 
the C-terminus. Two of eight phosphate ions are shown and are depicted as stick figures: phosphorus, orange; oxygen, red.Page 5 of 11
(page number not for citation purposes)
BMC Structural Biology 2008, 8:42 http://www.biomedcentral.com/1472-6807/8/42Activation mechanism of mammalian adenylate cyclase).
In particular, helix α1 moves towards helix α4 of the
opposite subunit, such that a triphosphate interaction site
is formed from the helix α1 dipole and a P-loop-like struc-
ture between strand β1b and helix α1. The N-terminal end
of strand β4, the C-terminal end of strand β1, and the N-
termini of helices α2 and α3 also shift towards the active
site, properly orienting metal-binding and triphosphate-
binding residues for catalysis.
Comparison of our guanylate cyclase catalytic domain
structure to structures of the mammalian adenylate
cyclase suggests that the guanylate cyclase catalytic
domain is in an inactive conformation. The dimethyl-
arsenic modifications described above clearly distort sev-
eral active site residues. But, in addition to these localized
changes, the overall orientation of one subunit with
respect to the other corresponds to an open state that must
close considerably for catalysis to occur, as we discuss fur-
ther below.
The signature structural change upon activation for all
adenylate cyclases is the movement of helix α1 towards
the active site and helix α4 in the opposite subunit,
regardless of other changes in domain orientations. In our
structure, a phosphate ion is bound to the N-terminal end
of helix α1 and to the P-loop-like site, suggesting the pres-
ence of a likely triphosphate-coordination site. However,
when monomer A of the guanylate cyclase structure is
superimposed on the active adenylate cyclase C1 domain,
helix α1 has not moved towards the active site, which
must occur to properly align all the catalytic residues, bind
nucleotide, and achieve an active conformation (Figure
4). Instead, the conformation of helix α1 in the guanylate
cyclase structure is much closer to that of helix α1 in the
inactive adenylate cyclase structure (compare Figure 4 and
Additional file 2: Activation mechanism of mammalian
adenylate cyclase). Activation of the guanylate cyclase
domains in the structure reported here would require the
N-terminus of helix α1 of each monomer to move ~3 Å
towards helix α4 of the other monomer, resulting in the
concomitant shifting of the ends of strands β1b and β4a
inwards towards the opposite monomer, and leading to
an active site configuration similar to that observed for the
mammalian adenylate cyclases (Figure 4).
Active site cooperativity
The mammalian adenylate cyclase catalytic domain het-
erodimer contains one active site and one catalytically
non-functional site – each monomer is missing residues
required for catalysis, which are provided by the other
monomer. The homodimeric nature of the guanylate
cyclase catalytic domain described here suggests that it
contains two active sites. In fact, the existence of two
active sites has been postulated for mammalian mem-
brane guanylate cyclases, all of which function as
homodimers [50]. We sought to confirm this possibility
by looking for evidence of cooperativity in activity assays.
Activity assays were carried out in the presence of Mn2+,
because the activity in the presence of Mg2+ was less than
1% of that in the presence of Mn2+ (data not shown), as
seen for mammalian soluble guanylate cyclase catalytic
Comparison between guanylate and adenylate cyclase active sitesFigure 3
Comparison between guanylate and adenylate 
cyclase active sites. Monomer B of the guanylate cyclase 
catalytic domain was superimposed onto the C2 domain of 
mammalian adenylate cyclase (PDB ID: 1CJU) [49]. Residues 
and structural elements involved in catalysis and nucleotide 
recognition are shown. A) Comparison of guanylate and ade-
nylate cyclase catalytic residues. B) Comparison of guanylate 
and adenylate cyclase base recognition residues. Side chains 
and structural elements from the guanylate cyclase and ade-
nylate cyclase catalytic domains are colored green and grey, 
respectively. The nucleotide 2',3'-dideoxyadenosine triphos-
phate (ddATP) and the two Mg2+ ions are from 1CJU. Non-
carbon atoms are colored as follows: phosphorus, orange; 
oxygen, red; nitrogen, blue; sulfur, yellow; arsenic, violet; 
magnesium, white.Page 6 of 11
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cooperativity, with a Hill coefficient of 1.5 (Figure 5),
indicating the presence of more than one active site and
providing evidence that the active sites interact with each
other. Cooperativity has also been observed for other
homodimeric cyclases, such as the mammalian mem-
brane-bound guanylate cyclases [51-53], as well as some
bacterial adenylate cyclases [54,55]. A possible mecha-
nism for communication between the mammalian ade-
nylate cyclase active site and the pseudosymmetric site,
where the activator forskolin binds, has been proposed. In
the mammalian adenylate cyclase catalytic domain het-
erodimer, the β2–β3 loop of the C1 monomer, which
contains a catalytically essential aspartic acid, is connected
via a hydrogen bond and a hydrophobic interaction to the
β2–β3 loop of the C2 monomer, which forms part of the
forskolin binding site. These interactions between the for-
skolin binding site and the active site provide a possible
mechanism by which the binding of forskolin is commu-
nicated to the catalytic residues in the active site, resulting
in activation [35].
In the absence of nucleotide, it is not clear in our structure
how occupation of one active site by nucleotide is
detected by the other. The analysis is also complicated by
the local distortions near the active site caused by the
dimethylarsenic-modified cysteines. However, inspection
of our structure provides two possible mechanisms for
communication between the active sites. The first mecha-
nism involves a direct connection between residues in the
two active sites. The β2–β3 loop of each monomer carries
both the invariant catalytic residue Asp 527 for one active
site and the conserved guanine-binding residue Glu 523
for the opposite active site. We propose that the interac-
tion of either Asp 527 or Glu 523 with nucleotide in one
active site could alter the conformation of the loop in
which they both reside, resulting in a change in nucleotide
affinity or enhanced catalysis in the other active site. The
second mechanism involves propagation of local changes
in one active site, through changes in elements of second-
ary structure, to the other active site. As noted above, upon
substrate binding, helix α1 and strands β1 and β4 in mon-
omer A move inward towards crucial residues in helix α4
Proposed guanylate cyclase activation mechanismFigure 4
Proposed guanylate cyclase activation mechanism. Comparison of helix α1 in the guanylate cyclase structure with helix 
α1 of the active mammalian adenylate cyclase structure indicates that the guanylate cyclase structure is in an inactive state. 
Monomer B of the guanylate cyclase structure was superimposed onto the C2 domain of the active adenylate cyclase structure 
(PDB ID: 1CJU) [49] and monomer A was superimposed onto the C1 domain of the same adenylate cyclase structure. The C2 
domain is omitted for clarity. The C1 domain of the active adenylate cyclase structure is colored blue, and the guanylate 
cyclase structure is colored green. The nucleotide 2',3'-dideoxyadenosine triphosphate (ddATP) and Mg2+ ions from 1CJU are 
shown as a stick figure and spheres: phosphorus, orange; oxygen, red; nitrogen, blue; magnesium, white.Page 7 of 11
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into correct alignment for catalysis in one active site (Fig-
ure 4). This movement also brings helix α4 of monomer
A, which lies directly above, and packs against, strands β1
and β4 of monomer A, towards monomer B. As helix α4
of monomer A carries residues necessary for catalysis at
the other active site, this movement might allow nucle-
otide binding at one active site to effectively begin pre-
organizing the other active site for nucleotide binding.
Interaction with regulators
The activating conformational transition of helix α1 and
attendant shift in adjacent β strands might be facilitated
by a domain rotation like that observed for the mamma-
lian adenylate cyclase C1 monomer upon Gsα binding
[35]. In the adenylate cyclases, the α1–α2 and α3–β4
loops of the C2 domain form a groove into which the
switch II helix of Gsα is docked. The docking of Gsα brings
about the rotation of the C1 domain. A similar groove is
found in the analogous location on the guanylate cyclase
dimer structure (Figure 6). It is tempting to speculate that
some regulatory element, such as a soluble guanylate
cyclase H-NOX sensor domain, might interact with this
region in an analogous fashion, altering the balance of
conformations in the catalytic domain. It is also possible
that interaction of regulators with entirely different struc-
tural elements, such as the C-terminal subdomains, may
be required to activate the guanylate cyclase catalytic
domain. Answers to such questions await the structure of
an active guanylate cyclase domain in the presence of reg-
ulatory elements.
Conclusion
We report the first structure of a eukaryotic guanylate
cyclase catalytic domain. The resemblance of the domain
to that of the mammalian adenylate cyclase is unsurpris-
ing, given the sequence and functional similarity between
them. Nevertheless, more than ten years have elapsed
between the first reports of the structures of the adenylate
cyclases [35,41] and our results, presented here. The diffi-
culty in crystallizing a guanylate cyclase domain may
reflect an increased intrinsic flexibility in the guanylate
cyclase domain relative to the adenylate cyclase domain,
and it is possible that we succeeded in part because of the
fortuitous cysteine modifications that may have increased
the rigidity of the domain, facilitating crystallization. We
have been unable as yet to crystallize the catalytic domain
in the absence of these modifications.
The high degree of sequence conservation between the
soluble guanylate cyclase catalytic domain described here
and the catalytic domains of mammalian soluble and
membrane-bound guanylate cyclases (40 to 50% identity)
suggests that our structure will serve as a superior model
for functional studies, compared to the mammalian ade-
nylate cyclase catalytic domains (25 to 30% sequence
identity). Our structure indicates that the differences
between the adenylate and guanylate cyclase are generally
localized to flexible regions, some of which are proposed
to mediate coupling with regulatory domains and other
control elements. While specific differences in regulatory
interactions are likely determined by the sequence and
local structure of these variable elements, the overall acti-
vation mechanism, involving conformational switching
by helix α1 and attendant changes in the adjacent β sheet,
is expected to be conserved.
Methods
Cloning and protein purification
PCR was used to amplify the gene encoding a 991-residue
soluble guanylate cyclase homolog CYG12 (GenBank:
XM_001700795) from a C. reinhardtii cDNA library
obtained from the Chlamydomonas Center [56]. Forward
Communication between active sitesFigure 5
Communication between active sites. Plot of guanylate 
cyclase activity at increasing concentrations of substrate 
GTP. Guanylate cyclase (5 μg) was incubated for 2 min at 24 
°C with the indicated concentrations of GTP in the presence 
of 4 mM MnCl2 and cGMP was measured. Data were fit to 
the equation , where Vmax is the maximum activ-
ity, S is the concentration of GTP, S0.5 is the substrate con-
centration at which half-maximal velocity is reached, and n is 
the Hill coefficient. From the fit, Vmax = 2795 ± 117 nmoles 
cGMP/min/mg, S0.5 = 269 ± 26 μM, and n = 1.49 ± 0.16. A Hill 
coefficient greater than 1 indicates the presence of interact-
ing active sites.
V S n
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BMC Structural Biology 2008, 8:42 http://www.biomedcentral.com/1472-6807/8/42and reverse PCR primers were 5'-ATGCTGGGCTGGTAT-
GACCGT-3' and 5'-TTACTCCAAACACGGGTTGTCA-3',
respectively. PCR products were phosphorylated, blunt-
cloned into the vector pGEM, and verified by sequencing
(UC Berkeley DNA Sequencing Facility). The guanylate
cyclase catalytic domain was expressed and purified using
a SUMO-based system (LifeSensors) as follows: residues
468–655, which comprise the catalytic domain of CYG12,
were subcloned into a vector containing the yeast SUMO
homolog SMT3 with an N-terminal His-tag, and the
fusion protein was expressed in Escherichia coli
Tuner(DE3) (Invitrogen) for 18 h at 20°C. The fusion
protein was purified from supernatant by passage over a
HisTrap Ni Sepharose affinity column (GE Healthcare). A
His-tagged version of the SMT3-specific protease was used
to cleave the N-terminal SMT3 fusion partner from the
guanylate cyclase domain, which was separated from the
protease and SMT3 by a second Ni affinity step. The gua-
nylate cyclase domain was further purified by Q Sepha-
rose anion-exchange chromatography, followed by gel
filtration into a final buffer of 25 mM triethanolamine,
pH 7.5, 25 mM NaCl, and 10 mM dithiothreitol. Purified
protein was concentrated and stored at -20°C until use.
Protein concentrations were determined by absorbance
using the calculated extinction coefficient ε280 = 7680 M-1
cm-1.
Crystallization and X-ray data collection
Crystals were grown using the sitting-drop vapor diffusion
method. Equal volumes (200 nl) of protein [40–60 mg/
ml in 25 mM triethanolamine, pH 7.5, 25 mM NaCl, 5–
10 mM dithiothreitol, 10 mM tris(2-carboxyethyl)phos-
phine] were mixed with crystallization solution [0.1 M
sodium cacodylate, pH 5.0–6.4, 42–62% saturated
(NH4)2HPO4] and then equilibrated with a 100-μl reser-
voir of the same crystallization buffer at 20°C. Crystals
grew in the trigonal space group and appeared within 1–2
days. Crystals were transferred to a solution of mother liq-
uor containing 28% glycerol as a cryoprotectant, and cryo-
cooled and stored in liquid nitrogen. Diffraction data
were collected at 100 K using synchrotron radiation at
beam line 8.2.2 at the Advanced Light Source, Lawrence
Berkeley National Laboratory. Reflections were integrated
and scaled with the programs MOSFLM [57] and SCALA
[58]. The structure was solved by molecular replacement
with the program PHASER [59] using the mammalian
adenylate cyclase catalytic domain (PDB code 1AZS) [35]
as the search model, and the space group was identified as
P3221. Map improvement was carried out using ARP/
wARP [60] and RESOLVE [61]. The model was built using
COOT [62] and refined using PHENIX [63]. Six TLS
domains were used during refinement: residues 467–475
and 578–595, monomer A/B; residues 476–560, 569–
577, and 596–608, monomer A/B; and residues 613–651,
monomer A/B. Analysis of model quality was carried out
A potential binding site for a regulatory control elementFigur  6
A potential binding site for a regulatory control ele-
ment. A) Structure of the mammalian adenylate cyclase cat-
alytic domain bound to the activator Gsα (PDB ID 1CJU) 
[49]. The switch II helix of Gsα binds in a groove on the C2 
domain between the α1–α2 and α3-β4a loops, priming the 
catalytic domain for nucleotide binding. A surface represen-
tation of the adenylate cyclase catalytic domain is shown, and 
Gsα is shown as a ribbon cartoon. The C1 domain is colored 
blue, the C2 domain is colored orange, and Gsα is colored 
teal. B) Surface representation of the guanylate cyclase cata-
lytic domain in the same orientation as the adenylate cyclase 
domain in A. A groove similar to that used by adenylate 
cyclase to bind to Gsα is located between the α1–α2 and α3-β4a loops, and may serve as a site for interaction of control 
elements with the guanylate cyclase catalytic domain. Mono-
mer A is colored teal, and monomer B is colored green.Page 9 of 11
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BMC Structural Biology 2008, 8:42 http://www.biomedcentral.com/1472-6807/8/42using MOLPROBITY [64]. Figures were prepared using
PYMOL [65]. The atomic coordinates and structure factors
have been deposited in the Protein Data Bank (3ET6).
Guanylate cyclase assays
Guanylate cyclase assays were performed in duplicate at
24°C as described previously [66]. Assays contained 5 μg
of guanylate cyclase in 25 mM triethanolamine, pH 7.5,
25 mM NaCl, 4 mM MnCl2 or MgCl2 and 5 mM dithioth-
reitol. Assays were initiated by addition of indicated
amounts of GTP, and were quenched after 2 minutes by
addition of 400 μl of 125 mM Zn(CH3CO2)2 and 500 μl
of 125 mM Na2CO3. cGMP was quantified using a cGMP
enzyme immunoassay kit, format B (Biomol), per the
manufacturer's instructions. Experiments were repeated
three times to ensure reproducibility.
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